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Abstract: Phosphoinositides are lipids involved in the vesicular transport of proteins and lipids
between the different compartments of eukaryotic cells. They act by recruiting and/or activating
effector proteins and thus are involved in regulating various cellular functions, such as vesicular
budding, membrane fusion and cytoskeleton dynamics. Although detected in small concentrations
in membranes, their role is essential to cell function, since imbalance in their concentrations is a
hallmark of many cancers. Their synthesis involves phosphorylating/dephosphorylating positions
D3, D4 and/or D5 of their inositol ring by specific lipid kinases and phosphatases. This process is
tightly regulated and specific to the different intracellular membranes. Most enzymes involved in
phosphoinositide synthesis are conserved between yeast and human, and their loss of function leads
to severe diseases (cancer, myopathy, neuropathy and ciliopathy).
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1. Phosphoinositides in Cellular Membranes
1.1. Lipids, Major Membrane Components
The dynamic modulation of the physicochemical properties of membranes is required for
eukaryotic cells function. Indeed, cells live in an environment characterized by temperature, relative
humidity, pH, sun exposure, osmotic pressure and nutrient variations. Living organisms have to adapt
to variations of these different factors in order to keep their intracellular balance. Eukaryotic cells
have achieved this by adopting a compartmentalized organization, which minimizes the intracellular
variations resulting from extracellular fluctuations. The plasma membrane is the first barrier separating
the cytoplasm from the extracellular medium. Its composition ensures a mechanical protection,
but also allows exchanges with the medium through transporters and receptors, as a form of very
selective permeability.
Membranes are composed of two phospholipid leaflets organized as a bilayer in which
sterols, glycolipids and proteins are inserted. The phospholipids of this bilayer are amphiphilic
with a hydrophilic group (head) linked to a hydrophobic group (tail) (Figure 1A). In the bilayer,
the hydrophobic groups face each other, thus creating a hydrophobic space in between them,
which ensures its role as a barrier. This property is very important for the anchoring of hydrophobic
molecules, such as sterols or ceramides, transmembrane domains or the lipid anchor of proteins.
The lipid composition of membranes varies according to the organism (eukaryotes or prokaryotes),
the cell type (among the different tissues of a multicellular organism), the membrane type (plasma
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membrane, endoplasmic reticulum, endosomes, Golgi and other intracellular compartments) or even
the state of the cell (quiescent or responding to stress or stimuli) [1,2].
Membranes are mainly composed of five phospholipids: phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PtdIns) and
sphingomyelin (SM). Sterols modulate the fluidity of the membrane, which is essential for the
lateral diffusion of molecules in the bilayer. The lipid bilayer of membranes has also an asymmetric
phospholipid composition between the inner and the outer leaflet, which partly results from the vertical
diffusion between the two leaflets by a flip-flop mechanism with a low intrinsic rate compensated by
the presence of proteins called flippases [3,4].
If the plasma membrane plays an essential role as a selective barrier, there are many more
intracellular membrane structures in eukaryotic cells, such as organelles and transport vesicles.
Both the organization, as well as the composition of these membranes depends on the nature of the
compartment. Indeed, the endoplasmic reticulum, the Golgi, lysosomes (vacuole in yeast), endosomes
and transport vesicles are surrounded by a single lipid bilayer. The inner space of these intracellular
compartments is called the lumen. On the other hand, the nucleus, mitochondria, chloroplasts and
autophagosomes are structures with at least a double lipid bilayer. Each of these compartments
performs specific functions necessary for the life of the cell [1]. Indeed, the vesicular transport of
proteins between compartments is regulated in a spatiotemporal manner. It is therefore vital that the
cell discriminates between compartments. This relies on the attribution of a specific identity to each
organelle and sometimes even to each face of an organelle, such as the cis and trans faces of the Golgi
apparatus. These identity cards are essentially defined by molecules present on the cytoplasmic leaflet
of membranes. Among these molecules, membrane lipids and more specifically phosphoinositides are
key players.
1.2. Phosphoinositides, Lipid Signaling Molecules
Phosphoinositide is a term used to describe the seven types of phosphorylated
phosphatidylinositol (PtdIns). Here, we use the abbreviation PPIn for phosphoinositides, since this
term is less ambiguous as PtdIns(s) or phosphoinositides (PIs). This PPIn term was first introduced by
Robert H. Michell and colleagues in a review [5]. Phosphoinositides (PPIn) are minor constituents of
cellular membranes, representing about 1% of total cellular phospholipids with phosphatidylinositol
representing about 10% [6]. PPIn are composed of glycerol esterified in positions SN1 and SN2 by two
fatty acid chains and linked in position SN3 to an inositol ring by a phosphate group (Figure 1A) [6].
In human, the most common fatty acids in PtdIns are stearic acid (18:0) in position SN1 and arachidonic
acid (20:4) in SN2 [7]. In the yeast Saccharomyces cerevisiae (S. cerevisiae), the nature of the fatty acids is
different with palmitic acid (16:0) in position SN1 and oleic (18:1) or palmitoleic acid (16:1) in SN2 [8].
The inositol ring of PPIn is a polyol cyclohexane of which positions D3, D4 and D5 can
be phosphorylated, generating seven possible PPIn (Figure 1B): phosphatidylinositol 3-phosphate
(PtdIns3P), PtdIns4P, PtdIns5P, PtdIns 3,4-bisphosphate (PtdIns(3,4)P2), PtdIns(3,5)P2, PtdIns(4,5)P2
and PtdIns 3,4,5-trisphosphate (PtdIns(3,4,5)P3). Despite their low concentration in membranes, PPIn
play an essential role in the recruitment and/or activation of effector proteins. Moreover, their presence
in a given membrane and their levels are determined by lipid kinases and phosphatases specific to
the different membranes, allowing the spatiotemporal regulation of various events, such as budding,
membrane fusion and dynamics [6].
1.3. Phosphatidylinositol, the Precursor of Phosphoinositides
PtdIns, the starting point of the PPIn metabolism, is a ubiquitous phospholipid in eukaryotic cells
present in various proportions according to the type of membrane. Indeed, PPIn are all metabolized
directly or sequentially from PtdIns (Figure 1). In S. cerevisiae, PtdIns is synthesized by the PtdIns
synthase 1 (Pis1) on the cytoplasmic face of the Endoplasmic Reticulum (ER), the Golgi, mitochondria
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and microsomes [9]. In human, its synthesis is catalyzed by a homologue of Pis1, the PtdIns synthase
with similar cell distribution as the yeast Pis1 [10].
PtdIns is also recycled by the conversion of PtdIns3P, PtdIns4P and PtdIns5P through
the action of the corresponding lipid phosphatase (Figure 1B). In human, myotubularin MTM1
and myotubularin-related phosphatases MTMR1-4, MTMR6 and MTMR7 are 3-phosphatases
dephosphorylating specifically the D3 position, thus producing PtdIns from PtdIns3P [11]. Less
specific phosphatases, such as Sac1, can dephosphorylate PtdIns3P in PtdIns, but also PtdIns4P and
probably PtdIns5P in PtdIns [12]. In S. cerevisiae, there is only one D3 specific phosphatase called Ymr1.
It shares this activity with other phosphatases, synaptojanin-like proteins (Sjl2 and Sjl3) and Sac1,
which also convert PtdIns4P in PtdIns [13].
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Figure 1. Phosphoinositides synthesized in yeast Saccharomyces cerevisiae (S. cerevisiae) and in
human cells with the enzymes involved. (A) The chemical structure of phosphatidylinositol (PI);
(B) Phosphorylation reactions are represented with black arrows and dephosphorylation reactions by
grey arrows. The name of the yeast enzyme (when relevant) is written on top of its human homologue.
2. PtdIns4P a Key Trafficking Effector for Phospholipids and Sterols
2.1. PtdIns4P Synthesis
PtdIns4P accounts for about 30% of total PPIn in yeast and approximately 45% in Human [6].
It is enriched at the Golgi where it is mainly produced by the phosphorylation of PtdIns by PtdIns
4-kinases [14]. It is also obtained after the dephosphorylation of PtdIns(4,5)P2 and PtdIns(3,4)P2
by PtdIns 5-phosphatases and PtdIns 3-phosphatases respectively (Figure 1B). In S. cerevisiae, the
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PtdIns 4-kinases Pik1 and Stt4 convert PtdIns in PtdIns4P at the Golgi and the plasma membrane
respectively [15]. Dephosphorylation of PtdIns(4,5)P2 in PtdIns4P is performed by the 5-phosphatases
Inp51/Sjl1, Inp52/Sjl2, Inp53/Sjl3 and Inp54 (Figure 1B). In Human, PPIn 4-kinases PI4Kα and PI4Kβ
synthesize PtdIns4P from the precursor PtdIns. Moreover, PtdIns4P is synthesized from PtdIns(3,4)P2
by the 3-phosphatase PTEN or from PtdIns(4,5)P2 by the 5-phosphatases OCRL1 (Occulocerebrorenal
syndrome protein 1), INPP5B (Inositol Polyphosphate Phosphatase 5B), INPP5E and synaptojanines 1
et 2 (Figure 1) [16]. Mutations affecting many of these lipid phosphatases are linked to diseases such as
Cowden and cancer for PTEN [17], Lowe syndrome for the OCRL1 [18], Joubert and MORM syndromes
(two ciliopathies) for the INPP5E [19,20] and Parkinson’s disease for the Synaptojanin 1 [21,22].
2.2. Physiological Role of PtdIns4P
PtdIns4P was for a long time merely considered as a precursor of other PPIn. In yeast, PtdIns4P is
present in two distinct compartments: the plasma membrane and the Golgi [15]. The Golgi is a central
node in membrane trafficking, where proteins and lipids from various intracellular compartments
get exchanged, thus requiring a tight spatiotemporal regulation of their sorting. PtdIns4P is thought
to be involved in Golgi trafficking [23]. Hence, in yeast, PtdIns4P was shown to have a function in
the anterograde transport from the trans-Golgi and the retrograde transport from the Golgi to the
endoplasmic reticulum [15]. In the anterograde transport, PtdIns4P is required for the formation of
secretory vesicles emanating from the Golgi and targeted to the plasma membrane [24]. Many proteins
interacting with PtdIns4P have been identified and localized at the Golgi [25]. Among them, seven
oxysterol binding protein homologues, termed Osh1 to Osh7, have been described, and most of them
were shown to transport lipids in association with PtdIns4P. Osh1, required for the transport of sterols,
localizes to the Golgi through its PH domain (pleckstrin homology), which interacts with PtdIns4P [26].
Osh4 extracts and transports ergosterol from the ER membrane to the Golgi, where it substitutes this
sterol for PtdIns4P, which is in turn transported backward from the Golgi to the ER [27]. Osh6 is a
phosphatidylserine (PS) phospholipid transporter that extracts PtdIns4P from the plasma membrane
(PM) to the ER where it is exchanged for PS to mediate its transport from the ER to the PM. At the ER,
Sac1 dephosphorylates PtdIns4P to maintain the PtdIns4P gradient driving this transport of PS [28].
The human OSBP (oxysterol binding protein) protein and the 12 OSBP-related proteins (ORP in the
human genome) are also involved in the intracellular transport of lipids in association with PtdIns4P.
OSBP localizes to the Golgi through the interaction of its PH domain with PtdIns4P. However, this
Golgi localization also requires a Golgi GTPase (ADP-ribosylation factor or ARF) [26]. OSBP exchanges
sterols for PtdIns4P between the ER and the Golgi, and at the ER, PtdIns4P is hydrolyzed in PtdIns
by the SAC1 phosphatase; the energy produced is further used for sterol transfer [29]. ORP5 and
ORP8, involved in PS transport between the ER and the plasma membrane, are localized to ER-PM
contact sites via the interaction of their PH (Pleckstrin Homology domain) domain with PtdIns4P [30].
ORP5 and ORP8 also localize to contact sites between the ER membrane and the mitochondria and are
required for mitochondrial functions [31]. The VAP proteins (VAPA and VAPB) are anchored at the
ER membrane, and their absence leads to a significant increase in the endosomal level of PtdIns4P
due to the impaired OSBP function (and probably other ORPs), a direct binding partner of VAP [32].
This lack of VAP proteins results in dysfunction of the endosome to Golgi membrane trafficking via
the retromer complex and the accumulation of actin comets between the endosome and the Golgi
involving the endosomal WASH (Wiskott–Aldrich syndrome homologue) complex [32]. FAPP1 and
FAPP2 (four-phosphate-adapter proteins 1 and 2) proteins, required for glycosphingolipid metabolism,
form a complex with ARFs at the Trans-Golgi Network (TGN) and interact with PtdIns4P through their
PH domain. They are involved in membrane sensing processes [25,33]. PI4Kα also produces PtdIns4P
at endosomes, the synthesis of which is required for receptor sorting at the early endosomes, maybe
via the EH Domain Containing 3 (EHD3) protein [34].
Recent studies on the primary cilium, an antennae projecting from the surface of the cell and
whose function or formation is altered in human diseases termed ciliopathies, show that they are
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enriched in PtdIns4P, whereas PtdIns(4,5)P2 is not detectable. However, upon inactivation of the
phosphoinositide 4-phosphatase INPP5E (observed in ciliopathies due to mutations in INPP5E),
its substrate the PtdIns(4,5)P2 (enriched at the plasma membrane) is detected at the ciliary tip where it
recruits its downstream effector TUL3P, which alters the Sonic hedgehog signaling (Shh) pathway [35].
3. Phosphatidylinositol 3-Phosphate (PtdIns3P) an Endosomal Lipid Essential in Membrane
Trafficking and Autophagy
3.1. PtdIns3P Synthesis
PtdIns3P accounts for about 30% of total PPIn in yeast and is as abundant as PtdIns4P. In human
cells, it represents less than 15% of monophosphorylated PPIn and is much less abundant than
PtdIns4P [6]. PtdIns3P is produced by the phosphorylation of PtdIns at position D3 of inositol or by
the dephosphorylation of PtdIns(3,4)P2 or PtdIns(3,5)P2 (Figure 1).
In S. cerevisiae, a single enzyme, the lipid kinase Vps34 (vacuolar protein sorting 34), catalyzes
specifically the phosphorylation of PtdIns in PtdIns3P [36,37]. The Vps34 kinase is activated via its
binding to the protein kinase Vps15, which is anchored to membranes. This Vps34-Vps15 complex
further recruits additional effectors to regulate either endosomal trafficking (via Vps38-Vps30 proteins)
or autophagy (via Atg14-Vps30) [38]. Interestingly, it has been shown that the positive regulation
of Vps34 by Vps15 is stimulated by the direct interaction between the C-terminal region of Vps15
constituted by seven repeats of the WD (Trp-Asp) domains and the Gα subunit Gpa1. Thus, this
C-terminal domain could behave as a γ subunit of the yeast G protein. This would result in a coupling
between the G protein mediated signaling at the plasma membrane and receptor sorting at the
endosomes. Moreover, the interaction of the Vps34-Vps15 complex with Gpa1 stimulates PtdIns3P
production on endosomes [39].
The human genome encodes eight lipid kinases able to phosphorylate PtdIns at the D3 position,
which are classified into three categories according to their substrate specificity and homology [40,41]:
- Two members of the class I phosphoinositide 3-kinases (PI3KC), which phosphorylate
predominantly PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3
- Three members of the class II phosphoinositide 3-kinases (PIK3C2), which predominantly
phosphorylate PtdIns4P to generate PtdIns(3,4)P2
- One member of the class III phosphoinositide 3-kinase (homologous to the yeast Vps34 lipid
kinase). As Vps34, the human PIK3C3 is specific for PtdIns and is consequently most probably
the biggest source of cellular PtdIns3P. The regulatory subunit of VPS34/PIK3C3 is the protein
p150/PIK3R4, the homologue of the yeast Vps15 [42]. A phylogenetic study suggests the
co-evolution of VPS34/PIK3C3 and its regulatory subunit VPS15/PIK3R4 in most eukaryotes,
from yeast to human and plants and in many protists, such as amoeba [43]. However, a recent
study shows that in human cells, VPS15 has an additional function in trafficking from Golgi to
primary cilia, independent from its association with VPS34, and that a missense mutation in the
VPS15 gene is responsible for ciliopathy [44].
In yeast, PtdIns3P is also synthesized by the lipid phosphatases Fig4 (factor induced gene 4, also
known as Sac3), Sjl2/Inp52, Sjl3/Inp53 and Sac1. They all possess a SAC catalytic domain able to
dephosphorylate PtdIns(3,5)P2 in PtdIns3P [16]. Fig4 is the sole PtdIns 5-phosphatase specific for
PtdIns(3,5)P2 [45]. Its human homologue FIG4/SAC3 fulfills similar cellular functions. Mutations in
the human FIG4 gene cause Charcot-Marie-Tooth type 4J disease, a recessive neuromuscular disease
characterized by neuron demyelination [16]. With MTM1, MTMR2, MTMR5 and MTMR13, FIG4 is
thus the fifth gene encoding a lipid phosphatase involved in a neuromuscular disease [46]. Indeed,
mutations in the gene coding for the lipid phosphatase MTM1 cause X-linked myotubular myopathy
(XLMTM), also known as centronuclear myopathy, likely by deregulating PtdIns3P metabolism [47].
Indeed, it was shown that the disruption of the PIK3C2B kinase resulted in a complete prevention of the
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myopathy phenotypes in a Mtm1 disease mouse model, and inhibition of the PIK3C2B kinase activity
after appearance of myopathy symptoms promoted a striking rescue in the zebrafish model [48].
3.2. Physiological Role of PtdIns3P
In the yeast S. cerevisiae, the deletion of the VPS34 gene is not lethal, but results in the very
slow growth of cells and reduced resistance to numerous stress factors (temperature, pH, ethanol,
hygromycin B, hyperosmotic stress, caffeine or rapamycin). The yeast vps34∆ mutant displays also
strong membrane trafficking defects, which result in an altered cell morphology, the defective vacuolar
transport of carboxypeptidase Y (CPY) and the absence of autophagy [38]. One of the essential roles of
Vps34 in trafficking is to ensure proper sorting of proteins to the vacuole by producing PtdIns3P, the
latter allowing the recruitment of endosomal effector proteins [49]. PtdIns3P production by Vps34 is
also critical for autophagy, since it regulates autophagosome formation [50]; the PROPPIN Atg18 and
Hsv2 proteins, which contain two binding sites for PtdIns3P, are critical for this process [51].
In yeast and mammalian cells, PtdIns3P is enriched at endosomal membranes and membranes
of intraluminal vesicles of the multivesicular body (MVB) [52]. At the early endosomes, it plays a
central role in recruiting effector proteins, such as the yeast Vps27 protein or its human homologue Hrs
(hepatocyte growth factor-regulated tyrosine kinase substrate), subunits of the ESCRT-0 (endosomal
sorting complex required for transport) complex are involved in the endosomal sorting of proteins
and the formation of the MVB [49]. They both have a FYVE domain (Fab1, YGL023, Vps27 and EEA1),
which interacts with endosomal PtdIns3P [53]. Similarly, the PtdIns3P 5-kinase Fab1 (S. cerevisiae) or
its human homologue PIKfyve, catalyzes the phosphorylation of PtdIns3P in PtdIns(3,5)P2, after their
interaction with PtdIns3P mediated by a FYVE domain [6]. Hence, one of the physiological roles of
PtdIns3P is to serve as a precursor for PtdIns(3,5)P2.
The human adapter protein EEA1 (early endosomal antigen 1) has a high affinity for PtdIns3P
through its FYVE domain and regulates endosomal membrane fusion processes by recruiting the
GTPase Rab5 to endosomes [53].
However, studies show that Hrs is not required for MVB formation, but rather for lysosomal
targeting and that it is the sorting nexin SNX3 that is required for MVB formation via binding to
PtdIns3P through its Phox-homology PX domain [54,55]. Indeed, the PX domain was shown to
preferentially bind to PtdIns3P, and these domains are found in the sorting nexin SNX proteins [56].
The SNX proteins are involved in endosomal sorting; some belong to the retromer complex (SNX1,
SNX2, SNX5 and SNX6) that allows the transport of proteins from the endosomes to the trans-Golgi
network, and some others (SNX4, SNX7 and SNX30) are involved in recycling from the endosomes to
the plasma membrane [57].
In human, upon autophagy induction, a protein complex comprising VPS34, VPS15, Beclin1 and
ATG14 is formed at ER membranes, where the lipid kinase activity of VPS34 leads to the formation
of PtdIns3P-enriched regions [58]. The latter then serve as platforms to recruit the double FYVE
domain-containing protein 1 (DFCP1) and the WD-repeat protein interacting with phosphoinositides
(WIPI) proteins, which are homologous to the yeast Atg18 [59–61]. DFCP1 interaction with PtdIns3P
promotes its translocation to an ER-localized punctate compartment enriched in PtdIns3P and
autophagosomal proteins. This structure, later termed omegasome by Polson and colleagues, initiates
the autophagosome formation [59]. WIPI 1 and 2 are PtdIns3P effectors, and their absence leads to
the accumulation of omegasome (PtdIns3P-positive ER structures) [60]. Moreover, WIPI 1 and 2 are
essential for the recruitment of the downstream autophagy partners Atg12, Atg5 and Atg16L and,
thus, for the subsequent steps of the autophagy process [62]. Indeed, mutations affecting the binding
of human WIPI proteins to PtdIns3P have been observed in cancers and neurodegenerative diseases,
indicating an important biological role of PtdIns3P in the regulation of autophagy and beyond [61].
Moreover, PtdIns3P patches formed at the ER membrane by Vps34/PIK3C3 in human cells also
serve as a scaffold for the formation of the double membrane enclosed vesicles needed for hepatitis
C (HCV) virus genome replication. Indeed, whereas the complete viral cycle of HCV takes place in
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the cytoplasm, the genome replication is done in double membrane vesicles that originate from the
cup-like structures built after the interaction of PtdIns3P with DFCP1, as do autophagosomes [63].
4. PtdIns5P, an Underappreciated Phosphoinositide
4.1. PtdIns5P Synthesis
PtdIns5P is the most recently identified monophosphorylated PPIn [64]. It was underappreciated
for a long time due to its very low basal concentration in mammalian cells, but also due to technical
difficulties in separating it from PtdIns4P. These technical issues were partly alleviated by new
methods used to detect PtdIns5P [65]. In basal mammalian cell conditions, PtdIns5P represents
less than 10% of monophosphorylated PPIn [6]. In humans, PtdIns5P can be produced directly
from PtdIns by the PIKfyve lipid kinase or by dephosphorylation of PtdIns(3,5)P2 by myotubularin
3-phosphatases [43,66–69] (Figure 1B). Cells expressing the oncogenic NPM-ALK (nucleophosmin
(ribosome biogenesis regulator) and anaplastic lymphoma kinase (tyrosine kinase receptor)) fusion
have high levels of PtdIns5P produced by PIKfyve [67] (Bergalet et al., 2015). In vivo, PIKfyve
overexpression results in an increase in PtdIns5P, whereas PIKfyve+/null heterozygous mice have lower
PtdIns5P levels compared to control mice, without displaying a negative effect on mice viability [68].
The major source of PtdIns5P in human cells comes from the action of the myotubularins, a family of
phosphoinositide 3-phosphatases associated to different diseases: X-linked centronuclear myopathy
(MTM1), Charcot-Marie-Tooth CMT4B1 (MTMR2), CMT4B2 (MTMR13) and CMT4B3 (MTMR5) [46,70].
In human cell cultures and in myotubes, the founder member of this family, named myotubularin
MTM1, dephosphorylates PtdIns(3,5)P2 in PtdIns5P [71]. The myotubularin-related phosphatase
MTMR3 in coordination with the PIKfyve kinase produces PtdIns5P in response to FGF-1 (fibroblast
growth factor) in Drosophila fibroblasts, which is required to stimulate cell migration [69]. In human,
high levels of PtdIns5P are also produced from plasma membrane PtdIns(4,5)P2 by the bacterial IpgD
4-phosphatase upon infection by Shigella flexneri, the causative agent for dysentery [72].
This PPIn seems to be specific for Metazoa, since no PtdIns5P has been detected in wild-type
S. cerevisiae strains. This is consistent with the fact that Ymr1, the unique yeast myotubularin, does not
have any 3-phosphatase activity towards PtdIns(3,5)P2 [13,73].
4.2. Physiological Role of PtdIns5P
The role of PtdIns5P in mammalian cells is still poorly understood, and expression of bacteria IpgD
is the best means so far to address the physiological roles of PtdIns5P. Indeed, initially, the first function
of PtdIns5P in human cells was discovered after observing the plasma membrane rearrangement and
actin cytoskeleton reorganization induced by the expression of IpgD [72]. A fraction of PtdIns5P is
also found in the nucleus, where it could be involved in stress response in particular by modulating
the transcriptional activity of chromatin regulator ING2. ING2 is the first protein in which the PHD
finger (Plant HomeoDomain), a zinc finger domain, has been shown to specifically bind PtdIns5P [74].
The PH domain of Dok (downstream of tyrosine kinase) proteins also shows a strong binding to
PtdIns5P, and this binding activates the phosphorylation of Dok proteins in T cell signaling [75].
Moreover, PtdIns5P was also shown to be involved in plasma membrane and endosomal functions.
At the plasma membrane, elevation of intracellular levels of PtdIns5P activates the Rho GTPase Rac1
by specifically binding to the guanine nucleotide exchange factor (GEF) Tiam1, via its C-terminal PH
domain, which drives actin remodeling [76]. The endosomal adapter TOM1 interacts directly with
PtdIns5P, and this interaction delays the endosomal internalization of the EGF receptor, showing that
PtdIns5P is a regulator of endosomal protein sorting [77]. The addition of PtdIns5P to cells increases
the number of autophagosomes and PtdIns5P sustains autophagy in cells treated with the VPS34
inhibitor wortmannin or knocked down for VPS34, thus in cells depleted for PtdIns3P [78].
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5. PtdIns(4,5)P2, a Phosphoinositide Involved in Actin Dynamics and in Endocytosis
5.1. PtdIns(4,5)P2 Synthesis
In yeast, PtdIns(4,5)P2 is as abundant as PtdIns4P, that is about 30% of total PPIn and 90% of the
different bisphosphorylated PPIn. In human, it represents about 45% of total PPIn and more than 90%
of the different bisphosphorylated PPIn. PtdIns(4,5)P2 is thus the most abundant PPIn [79].
PtdIns(4,5)P2 is synthesized by the PPIn 5-kinase Mss4 in yeast (Figure 1) and is mainly localized
at the plasma membrane (Figure 2) [80].
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In human, many PPIn-kinases synthesizing PtdIns(4,5)P2 have been identified: type I PIP5Kα, β
and γ are localized at the plasma membrane and convert PtdIns4P into PtdIns(4,5)P2 [81], whereas
type II PIP4K are localized at the Golgi and convert PtdIns5P into PtdIns(4,5)P2 [82,83]. The type I
PIP5Kβ forms homo- and hetero-dimers with the PIP5Kγ in vitro and in vivo in human cells, and this
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dimerization is essential for enzymatic activity and plasma membrane localization [84]. In mammalian
cells, but not in yeast, PtdIns(4,5)P2 is also produced from PtdIns(3,4,5)P3 by dephosphorylation by
PPIn 3-phosphatases, such as PTEN (phosphatase and tensin homolog), TPIPα, β and γ (Figure 1) [16].
5.2. Physiological Role of PtdIns(4,5)P2
In S. cerevisiae and in human cells, PtdIns(4,5)P2 is most abundantly present in the cytoplasmic
leaflet of the plasma membrane (Figure 2), where it acts as a major actin cytoskeleton and endocytic
regulator. In S. cerevisiae, Mss4 acts in combination with the PtdIns 4-kinase Stt4 at the plasma
membrane to generate PtdIns(4,5)P2 from PtdIns. This PPIn is essential for the activation of the MAP
kinase Rho1/Pkc1-mediated signaling cascade. Indeed, proper localization of Rom2, the GEF of the
Rho1 GTPase, depends directly on the interaction of its PH domain with membrane PtdIns(4,5)P2 [85].
Actin cytoskeleton organization depends in large part on this signaling pathway [80]. Mss4 activity
and PtdIns(4,5)P2 synthesis fulfill other important functions in endocytosis, which is actin-dependent
in yeast [86]. Indeed, effector proteins of endocytosis, such as those with an ENTH (Epsin N-terminal
homology), ANTH (AP-180 N-terminal homology) or PH (Pleckstrin homology) domain all interact
with PtdIns(4,5)P2 [87,88]. Among them, the yeast rhomboid protein Rbd2 directly binds PtdIns(4,5)P2
to regulate and control clathrin-mediated actin-dependent endocytosis [89]. Rbd2 acts in coordination
with the syndapin-like protein Bzz1 to control type I myosin-dependent actin polymerization at the
sites of endocytosis [89,90].
In mammalian cells, PtdIns(4,5)P2 is mainly required at the plasma membrane for the actin
regulation of clathrin-mediated endocytosis (Figure 2) [79]. Different effector proteins required for the
internalization step of endocytosis have an ENTH, ANTH or PH domain, which interacts specifically
with PtdIns(4,5)P2 [79,87,88]. For example, the ENTH domain of Epsin1 interacts with PtdIns(4,5)P2,
inducing a structural rearrangement resulting in the formation of an additional N-terminal α-helix
that inserts into the lipid bilayer and generates the membrane curvature required for the formation
of endocytic vesicles [91]. The SNX5 and SNX9 sorting nexins preferentially bind PtdIns(4,5)P2
over PtdIns3P and have a membrane remodeling BAR (Bin-amphiphysin-Rvs) domain at their
N-terminus [56,92,93]. At the plasma membrane, SNX9 directly binds to the 5-phosphatase OCRL-1,
which acts in the late stages of endocytic internalization to uncoat the vesicles and allow cargo
sorting by fusion of the vesicles with the endosomes [94]. At the endosomes of non-neuronal cells,
PtdIns(4,5)P2 signaling is turned off by the 5-phosphatase OCRL-1 under the spatiotemporal control
of the Rab35 GTPase [95]. P SNX5 is localized on early endosomes and specifically recruited at the
plasma membrane in response to EGF stimulation [96]. As in yeast, PtdIns(4,5)P2 also regulates actin
cytoskeleton dynamics. Indeed, several studies have shown the interaction of PtdIns(4,5)P2 with
actin polymerization regulators [97]. At the plasma membrane, two actin-binding proteins MIM
(Missing In Metastasis) and IRSp53 (Insulin Receptor Substrate Protein of 53 kDa) directly interact
with PtdIns(4,5)P2 to deform the membrane in coordination with actin cytoskeleton reorganization
to induce filopodia and promote cell motility [98]. Actin dynamics is regulated by different small
G-proteins (Rho, Rac, Cdc42, Arf) whose activity is modulated by PtdIns(4,5)P2 [99].
PtdIns(4,5)P2 has been detected in the nucleus, where it regulates pre-mRNA splicing [100].
Moreover, in the nucleus, PtdIns(4,5)P2 regulates the activity of a poly(A) polymerase, termed
Star-PAP (nuclear speckle targeted PIPKIalpha regulated-poly(A) polymerase) to selectively control
the expression of some targeted genes [101]. In humans, PtdIns(4,5)P2 plays also a major role in
regulating various signaling pathways, namely because of the rapid switching it can undergo thanks to
the different PPIn kinases and phosphatases using it as a substrate (Figure 1). Highly metastatic breast
cancer cells have reduced PtdIns(4,5)P2 levels at the plasma membrane, mainly due to upregulation of
enzymes using it as a substrate [102].
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6. PtdIns(3,5)P2, a Regulator of Endosome-Lysosome Trafficking
6.1. PtdIns(3,5)P2 Synthesis
PtdIns(3,5)P2 is a rare PPIn, since it represents less than 5% of total PPIn in S. cerevisiae and
human and is enriched in vesicular and tubular domains in late endosomes and at the vacuole
(yeast)/lysosome (HeLa cells) (Figure 2) [79,103].
In S. cerevisiae, PtdIns(3,5)P2 is sequentially synthesized by the PtdIns 3-kinase Vps34 from
PtdIns to generate PtdIns3P, which is then phosphorylated by the PtdIns3P 5-kinase Fab1 to generate
PtdIns(3,5)P2 (Figure 1). In response to osmotic stresses, PtdIns(3,5)P2 synthesis is stimulated, and
its intracellular level increases 20-fold compared to non-stressed cells [104]. The vacuolar membrane
proteins Vac7 and Vac14 are required for PtdIns(3,5)P2 synthesis [105]. Vac7 is the main activator of
Fab1 in response to osmotic shock, whereas Vac14 acts in a complex with the lipid phosphatase Fig4
to regulate PtdIns(3,5)P2 renewal [106]. This is rather surprising, because stimulating PtdIns(3,5)P2
synthesis in response to osmotic stress requires two antagonistic processes, PtdIns(3)P phosphorylation
in PtdIns(3,5)P2, as well as its dephosphorylation in PtdIns(3)P in a seemingly futile cycle [107]. This
shows an essential interdependence between lipid kinases and phosphatases in the regulation of
PtdIns(3,5)P2 synthesis.
In human, PtdIns(3,5)P2 synthesis is similar to yeast, and it is catalyzed by PIKfyve, the sole
PtdIns3P 5-kinase (Figure 1B) [108]. Up to now, no PPIn 4-phosphatase hydrolyzing PtdIns(3,4,5)P3 has
been characterized. Thus, the only pathway to synthesize PtdIns(3,5)P2 requires the phosphorylation of
PtdIns3P (Figure 1). Furthermore, the PtdIns(3,5)P2 synthesis pathway described in yeast is conserved
in human, with PIKfyve interacting with multiple partners [108]. This interaction is indirect and
requires the adapter protein ArPIKfyve/VAC14 to stabilize the complex and stimulate PIKfyve
activity [109]. As in yeast cells, VAC14 serves as a platform regulating PtdIns(3,5)P2 synthesis by
interacting directly with PIKfyve, FIG4/SAC3 and VAC7 to fine tune the regulation of PtdIns(3,5)P2
levels [109,110]. Mutation in the FIG4 gene causes Charcot-Marie-Tooth neuropathy [111], and the
Mtmr2 knock-out mice model for the disease has elevated PtdIns(3,5)P2 levels [112]. Moreover, there is
a genetic interaction between MTMR2 that dephosphorylates PtdIns(3,5)P2 and FIG4 that participates
in PtdIns(3,5)P2 synthesis since reduction of FIG4 rescues the myelin outfoldings phenotype of the
Mtmr2 KO mice [112]. Autosomal dominant mutations in FIG4 are also a rare cause of amyotrophic
lateral sclerosis and primary lateral sclerosis [113]. Biallelic mutations in the VAC14 gene are responsible
for neurological disease [114].
6.2. Physiological Role of PtdIns(3,5)P2
In S. cerevisiae, fab1∆ cells display a growth phenotype at 23 ◦C, which are unable to grow at 37 ◦C,
and vacuoles have an acidification defect, as well as being very enlarged, occupying up to 80% of
the cell volume. One of the consequences of these enlarged vacuoles is the incorrect segregation of
chromosomes during cell division [115]. Vac7 and Vac14, which regulate PtdIns(3,5)P2 synthesis, are
required to maintain the vacuolar morphology, as well as its proper inheritance between the mother
and the daughter cell [105].
PtdIns(3,5)P2 plays an essential role in protein sorting at the late endosomes/MVB (Figure 2) [116].
Membrane proteins destined for the vacuole are tagged with ubiquitin at the endosomes, recognized
by ESCRT-0 to -3 complexes for their recruitment at endosomal internalization sites and packaged into
the vesicles budding in the endosomal lumen, thus forming the MVB. The fusion of the latter with the
vacuole results in the delivering of these vesicles in the vacuolar lumen [49]. The mammalian VPS24
protein, a component of the ESCRT-3 complex, was shown to specifically bind PtdIns(3,5)P2 [117].
At the endosomes, yeast epsins Ent3 and Ent5 interact with PtdIns(3,5)P2 through their ENTH
domain and are required for endosomal sorting of ubiquitylated cargos and endosomal recycling of
SNARES [118–120]. To date, the yeast Atg18/Svp1 and Hsv2 proteins, belonging to the PROPPIN
family, show the highest affinity and specificity for PtdIns(3,5)P2; in vitro, these proteins are involved in
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autophagy [51,121]. These two proteins do also bind to PtdIns3P via two distinct sites [51]. Atg18/Svp1
regulates Fab1 activity by interacting with the regulatory protein Vac7 (itself recruited by the scaffold
protein Vac14). Consequently, Atg18/Svp1 could act as a PtdIns(3,5)P2 sensor by feedback regulating
of its synthesis through Vac7 and Vac14 [122].
In mouse, PIKfyve−/− knock-out is embryonically lethal at an early stage [68], underlining the
central role of this lipid in cellular processes. PIKfyve was described as having a role in various
processes, such as endosomal sorting of proteins, lysosomal homeostasis or signaling pathway
regulations [6]. At the endosomes, production of PtdIns(3,5)P2 induces the release of cortactin from
the endosomal branched actin network via direct interaction between the actin filament-binding
region of cortactin and PtdIns(3,5)P2. This regulation is important for membrane trafficking since
actin cytoskeleton dynamics regulates membrane curvature and transport of vesicles [123]. At the
central nervous system (CNS), PtdIns(3,5)P2 regulates oligodendrocytes differentiation by directing
endosomal trafficking of plasma membrane-derived myelin-associated glycoprotein (MAG) [124].
7. PtdIns(3,4)P2, a Lipid Secondary Messenger
7.1. PtdIns(3,4)P2 Synthesis
PtdIns(3,4)P2 is not detected in yeast S. cerevisiae. In human cells, it mainly localizes to the plasma
membrane (Figure 2) and represents less than 10% of total PPIn in basal conditions. Nonetheless, its
intracellular level can transiently increase in response to stimulations by growth factors or cytokines [6].
PtdIns(3,4)P2 is mainly produced by the phosphorylation of PtdIns4P into PtdIns(3,4)P2 by class II PI3K
lipid kinases (Figure 1B) [125]. PtdIns(3,4,5)P3 dephosphorylation into PtdIns(3,4)P2 is performed by
the PPIn 5-phosphatases SHIP1/INPP5D, SHIP2/INPPL1, OCRL1, INPP5B, as well as synaptojanins 1
and 2 (Figure 1) [16].
7.2. Physiological Role of PtdIns(3,4)P2
PtdIns(3,4)P2 acts as a secondary messenger by recruiting the protein kinases Akt (protein
kinase B) and PDK1 (phosphoinositide-dependent kinase 1) or Pleckstrin, the downstream effector
of protein kinase C (PKC) through their PH domain [126]. A transforming mutation in the PH
domain of Akt1 is associated with breast, colorectal and lung cancers; this mutation activates Akt1
by allowing its recruitment to membranes independently of its PtdIns(3,4)P2 and PtdIns(3,4,5)P3
binding [127]. The link between PtdIns(3,4)P2 and the PI3K/Akt signaling pathway suggests that this
PPIn could be involved in numerous biological processes, such as controlling the cell cycle, cell survival,
angiogenesis or glucose metabolism. The balance between PtdIns(3,4)P2 and PtdIns(3,4,5)P3 through
the interplay between lipid kinases and phosphatases (Figure 1) is essential in regulating signaling
pathways downstream of Akt [128]. The INPP4B phosphatase is acting as a tumor suppressor by
dephosphorylating the 4’-position of PtdIns(3,4)P2 and thus inhibiting the Akt signaling pathway [129].
Among the various protein domains binding PtdIns(3,4)P2, only the PH domains of TAPP1
(tandem PH domain containing protein 1) interact specifically with PtdIns(3,4)P2, the specificity of
which is due to an alanine residue of the binding domain [130,131]. Double knock-in mice of TAPP1
and TAPP2 affected in the PtdIns(3,4)P2 binding site display insulin sensitivity and increased activation
of Akt, a key player in insulin signaling, showing that in vivo PtdIns(3,4)P2 is a negative regulator of
the PI3K/Akt signaling pathway [132].
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8. PtdIns(3,4,5)P3, a Key Effector of the PI3K/Akt Signaling Pathway
8.1. PtdIns(3,4,5)P3 Synthesis
S. cerevisiae does not have detectable levels of PtdIns(3,4,5)P3, so this PPIn is considered absent
from this organism. In human, PtdIns(3,4,5)P3 represents less than 5% of total PPIn and is almost
undetectable in quiescent cells. However, its intracellular level rapidly and transiently increases up to
100-fold in response to an agonist [133]. PtdIns(3,4,5)P3 is mainly synthesized at the plasma membrane
(Figure 2) by class I PPIn 3-kinases from PtdIns(4,5)P2 (Figure 1), but small pools of PtdIns(3,4,5)P3 can
be found at the membrane of other intracellular compartments in response to agonists [6].
The synthesis of PtdIns(3,4,5)P3 is tightly regulated given that this signaling molecule is at the
center of many signaling pathways. Among the regulators of its intracellular levels, there is the PTEN
phosphatase, which catalyzes the dephosphorylation of PtdIns(3,4,5)P3 on position D3 to produce
PtdIns(4,5)P2. PTEN has also been characterized as a tumor suppressor; indeed, mutations in the
PTEN gene are linked to many cancers [16]. The main role of PTEN is to regulate the cell cycle and
apoptosis through its phosphatase activity, which is required for the regulation of the PI3K/Akt
signaling pathway.
8.2. Physiological Role of PtdIns(3,4,5)P3
Despite being present at very low levels, PtdIns(3,4,5)P3 is the PPIn with the best characterized
cellular functions. Indeed, its effectors are involved in many signaling pathways and interact with
it through their PH domain. Among its effectors, we can cite small GTPases of the Arf family
(ADP-ribosylation factors), the serine/threonine kinases PDK1 and Akt, as well as phospholipase C γ
(PLCγ). Thus, PtdIns(3,4,5)P3 controls key cellular functions, such as cell proliferation and cell survival,
cytoskeleton dynamics, cell motility, membrane trafficking and apoptosis [25,97]. The deregulation of
PtdIns(3,4,5)P3 intracellular levels results in the development of many diseases.
One of the most studied functions of PtdIns(3,4,5)P3 is the regulation of the Akt kinase. Akt plays
a very important, role on the one hand, by activating the class I PI3KC I and PtdIns(3,4,5)P3 synthesis
and, on the other hand, by activating PDK1 at the plasma membrane after its membrane recruitment
through the interaction of its PH domain with PtdIns(3,4,5)P3 [128]. There are three Akt isoforms, Akt1
to Akt3, which are activated by growth factors or other extracellular stimuli, as well as by oncogenic
mutations in different regulators of Akt (Ras, subunits p110 and p85 of class I PI3KC and PTEN).
Indeed, the PH domain of Akt also interacts with PtdIns(3,4)P2 produced by SHIP dephosphorylation
of PtdIns(3,4,5)P3 (Figure 1) [128]. Perturbations in the PtdIns(3,4,5)P3/PtdIns(3,4)P2/Akt signaling
pathway lead to cancers, diabetes and cardiovascular and neurological diseases. Many of the
inhibitors/antagonists commonly used in therapies act on the interaction between PPIn and the
PH domain of Akt [128]. PtdIns(3,4,5)P3 also promotes rearrangements of the actin cytoskeleton in
response to growth factors via the activation of the Rho GTPase Cdc42 that mediates filamentous actin
assembly. This dynamic assembly of actin plays an important role in the translocation of the meiotic
spindle from the center of the oocyte to the cortex [97,134].
9. Conclusions
Phosphoinositides are lipid molecules coordinating and regulating intracellular trafficking.
The synthesis of these different PPIn is temporally and spatially controlled by the interplay between
lipid kinases and phosphatases in response to stimuli. The seven potential PPIn lipids are present
in most cell types at various levels with most species enriched in a given intracellular compartment.
All PPIn are virtually interconvertible as long as the organism has the appropriate set of enzymes
for their metabolism. This explains why PtdIns5P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3, are present
in mammalians and have not been detected in the yeast S. cerevisiae. PPIn play an essential role in
defining the identity of intracellular membranes. Moreover, local changes in PPIn levels allow the
fine regulation of key cellular events, such as vesicular budding, membrane fusion or the dynamics of
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trafficking. Given their low abundance (less than 10% of cellular phospholipids), PPIn can be locally
subjected to strong variations of their concentration. This is particularly the case for PtdIns(3,4,5)P3 in
response to stimuli in mammalian cells and for PtdIns(3,5)P2 in response to an osmotic shock in yeast.
Therefore, many studies have been and will have to be done to understand the metabolism of PPIn,
their localization and intracellular functions. Indeed, despite their low levels, they play essential roles
in the recruitment and/or activation of effector proteins and are involved in the regulation of many
cellular functions.
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